NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Executive Summary

• NeuroThera Labs announced that its collaborator Clearmind Medicine has filed a patent application in Hong Kong for a novel combination therapy (MEAI + PEA) targeting major depressive disorder (MDD).
• The filing highlights the potential of this non‑hallucinogenic neuroplastogen to offer a safer, more accessible and affordable alternative to existing antidepressants.
• The announcement underscores ongoing collaboration between NeuroThera and Clearmind and may enhance the company’s IP portfolio and future commercial prospects.

Key Details

• Patent application filed by Clearmind Medicine with the Intellectual Property Department of Hong Kong, China for a combination of Clearmind’s proprietary 5‑methoxy‑2‑aminoindane (MEAI) and NeuroThera‑sourced Palmitoylethanolamide (PEA).
• Therapy is positioned as a non‑hallucinogenic neuroplastogen intended to treat major depressive disorder, affecting >332 million people worldwide.
• Company describes the combination as potentially safer, more accessible, and more affordable than current antidepressants such as SSRIs.
• Collaboration between NeuroThera Labs (TSXV: NTLX) and Clearmind Medicine Inc. (Nasdaq: CMND) continues under existing agreements; no new financial terms disclosed.
• Forward‑looking statements note early‑stage development risks, uncertainty of clinical outcomes, and the possibility that the patent may not be granted or provide sufficient protection.

Notable Quotes

(No direct quotes were provided in the release.)